US4420568A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fluorescent polarization immunoassay utilizing substituted triazinylaminofluoresceins
Assignee: Abbott Laboratories
•
Filing: 1981-11-30
•
Granted: 1983-12-13
•
Expires: 2001-11-30
Abstract
Abstract An immunochemical method and reagent compounds for determining ligands in a sample. The reagent compounds are derivatives of a triazinylaminofluorescein and are represented by the structural formula <IMAGE> wherein Y is halo or lower alkyl; and R is a ligand-analog wherein said ligand-analog has at least one common epitope with said ligand so as to be specifically recognizable by a common antibody. The reagent compound and an antibody specific to the ligand are added to the sample in a fluorescence polarization immunoassay.
Inventors
- 👤 Chao-Huei J. Wang
- 👤 Stephen D. Stroupe
- 👤 Michael E. Jolley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 06:08
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/20; C07H15/22; C07H15/222; C07H15/226; C07H15/234; C07D; C07D473/00; C07D473/02; C07D473/04; C07D473/06; C07D473/08; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/532; G01N33/533; Y; Y10; Y10S; Y10S436/00; Y10S436/80; Y10S436/815; Y10S436/817
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
95 words
A method for determining ligands in a sample comprising intermixing with said sample a biologically acceptable salt of a tracer of the formula: ##STR37## wherein Y is halo or lower alkyl; and R is a ligand-analog wherein said ligand-analog has at least one common epitope with said ligand so as to be specifically recognizable by a common antibody; and an antibody capable of specifically recognizing said ligand and said tracer; and then determining the amount of tracer bound to antibody by fluorescence polarization techniques as a measure of the amount of ligand in the sample.
Claim 2
Independent Claim
95 words
A method for determining ligands in a sample comprising intermixing with said sample a biologically acceptable salt of a tracer of the formula: ##STR37## wherein Y is halo or lower alkyl; and R is a ligand-analog wherein said ligand-analog has at least one common epitope with said ligand so as to be specifically recognizable by a common antibody; and an antibody capable of specifically recognizing said ligand and said tracer; and then determining the amount of tracer bound to antibody by fluorescence polarization techniques as a measure of the amount of ligand in the sample.
Claim 3
Dependent Claim
15 words
A method according to claim 1 wherein said biologically acceptable salt is a sodium salt.
Claim 4
Dependent Claim
26 words
A method according to claim 2 wherein said ligand is a steroid, hormone, antiasthamatic, antineoplastic, antiarrhythmic, anticonvulsant, antibiotic, antiarthritic, antidepressant, cardiac glycoside, or a metabolite thereof.
Claim 5
Dependent Claim
19 words
A method according to claim 3 wherein R has a molecular weight within a range of 50 to 4000.
Claim 6
Dependent Claim
19 words
A method according to claim 4 wherein R has a molecular weight within a range of 100 to 2000.
Claim 7
Dependent Claim
10 words
A method according to claim 5 wherein Y is halo.
Claim 8
Dependent Claim
12 words
A method according to claim 6 wherein said ligand is an antibiotic.
Claim 9
Dependent Claim
11 words
A method according to claim 7 wherein said antibiotic is vancomycin.
Claim 10
Dependent Claim
12 words
A method according to claim 7 wherein said antibiotic is an aminoglycoside.
Claim 11
Dependent Claim
11 words
A method according to claim 9 wherein said aminoglycoside is gentamicin.
Claim 12
Dependent Claim
12 words
A method according to claim 9 wherein said antibiotic aminoglycoside is tobramycin.
Claim 13
Dependent Claim
11 words
A method according to claim 9 wherein said aminoglycoside is amikacin.
Claim 14
Dependent Claim
11 words
A method according to claim 9 wherein said aminoglycoside is streptomycin.
Claim 15
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is an antiarrhythmic drug.
Claim 16
Dependent Claim
12 words
A method according to claim 14 wherein said antiarrhythmic drug is N-acetylprocainamide.
Claim 17
Dependent Claim
12 words
A method according to claim 14 wherein said antiarrhythmic drug is quinidine.
Claim 18
Dependent Claim
12 words
A method according to claim 14 wherein said antiarrhythmic drug is procainamide.
Claim 19
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is an anticonvulsant drug.
Claim 20
Dependent Claim
13 words
A method according to claim 18 wherein said anticonvulsant drug is valproic acid.
Claim 21
Dependent Claim
12 words
A method according to claim 18 wherein said anticonvulsant drug is phenobarbitol.
Claim 22
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is an antiarthritic drug.
Claim 23
Dependent Claim
12 words
A method according to claim 21 wherein said antiarthritic drug is salicylate.
Claim 24
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is an antidepressant drug.
Claim 25
Dependent Claim
12 words
A method according to claim 23 wherein said antidepressant drug is nortriptyline.
Claim 26
Dependent Claim
12 words
A method according to claim 23 wherein said antidepressant drug is amitriptyline.
Claim 27
Dependent Claim
12 words
A method according to claim 23 wherein said antidepressant drug is imipramine.
Claim 28
Dependent Claim
12 words
A method according to claim 23 wherein said antidepressant drug is desipramine.
Claim 29
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is an antiasthamatic drug.
Claim 30
Dependent Claim
12 words
A method according to claim 28 wherein said antiasthamatic drug is theophylline.
Claim 31
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is a steroid drug.
Claim 32
Dependent Claim
13 words
A method according to claim 6 wherein said ligand is a hormonal drug.
Claim 33
Dependent Claim
14 words
A method according to claim 6 wherein said ligand is a cardiac glycoside drug.
Claim 34
Dependent Claim
27 words
A method according to claim 2 wherein said ligand is a narcotic, hypnotic, sedative, analgesic, anasthetic, psychotogenic, muscle relaxant, nervous stimulant or anticholinesterase agent or its metabolite.
Claim 35
Dependent Claim
28 words
A method according to claim 2 wherein said ligand is a tranquilizer, histamine, antihistamine, neuromuscular blocking agent, diuretic, thyroid drug, antithyroid drug or hypoglycemic drug or its metabolite.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-12-12 | 1987-06-13 | 1987-12-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-12-12 | 1991-06-13 | 1991-12-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-12-12 | 1995-06-13 | 1995-12-13 | $7700.00 | Window Closed / Lapsed |